Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CEL-SCI Co. stock logo
CVM
CEL-SCI
$2.44
+1.2%
$4.87
$1.98
$66.60
$7.40M0.2776,146 shs63,480 shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.21
-4.0%
$1.00
$0.81
$1.76
$29.80M0.74128,978 shs67,240 shs
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
$1.13
-9.6%
$0.55
$0.11
$3.91
$40.62M0.1831.16 million shs4.38 million shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.46
+1.5%
$3.22
$2.57
$6.88
$21.07M0.639,061 shs3,739 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CEL-SCI Co. stock logo
CVM
CEL-SCI
+1.24%+6.55%-2.79%-65.93%-92.99%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-3.97%+15.79%+27.50%+18.63%-11.68%
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
-9.60%-24.67%+438.10%+402.22%+112,999,900.00%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+1.47%+0.61%+4.85%-1.14%-45.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.0605 of 5 stars
0.02.00.00.00.00.00.6
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.2392 of 5 stars
3.75.00.00.02.70.80.6
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.8237 of 5 stars
0.03.00.00.02.21.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00
N/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.33
Buy$10.00726.45% Upside
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
0.00
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest KLTO, CVM, ENLV, and NAII Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/3/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/A$0.15 per shareN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$1.00 per shareN/A
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/A$0.04 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CEL-SCI Co. stock logo
CVM
CEL-SCI
-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
-$6.15M-$0.36N/AN/AN/A-1,779.01%-275.01%N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A

Latest KLTO, CVM, ENLV, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.15+$0.01-$0.15N/AN/A
5/15/2025Q1 2025
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A-$0.08N/A-$0.08N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
3/31/2025Q4 2024
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.23-$0.07-$0.23N/AN/A
3/31/2025Q4 2024
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A-$0.07N/A-$0.07N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.66
1.07
1.09
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
7.20
7.20
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A
0.29
0.29
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35

Institutional Ownership

CompanyInstitutional Ownership
CEL-SCI Co. stock logo
CVM
CEL-SCI
12.08%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
1.02%
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
20.07%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%

Insider Ownership

CompanyInsider Ownership
CEL-SCI Co. stock logo
CVM
CEL-SCI
9.93%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
12.28%
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
26.70%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
CEL-SCI Co. stock logo
CVM
CEL-SCI
433.03 million64.67 millionOptionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7023.65 million20.75 millionOptionable
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A32.49 million23.82 millionN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable

Recent News About These Companies

Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results
CarnoSyn Brands announces new U.S. distribution pact with B&D Nutritional
(NAII) Trading Advice
In Asia, alternative proteins are the new clean energy

New MarketBeat Followers Over Time

Media Sentiment Over Time

CEL-SCI stock logo

CEL-SCI NYSE:CVM

$2.44 +0.03 (+1.24%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$2.42 -0.02 (-0.66%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.21 -0.05 (-3.97%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$1.21 0.00 (0.00%)
As of 06/26/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Klotho Neurosciences stock logo

Klotho Neurosciences NASDAQ:KLTO

$1.13 -0.12 (-9.60%)
As of 06/26/2025 04:00 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.45 +0.04 (+1.17%)
As of 06/26/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.